Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
An Open-label Phase 3 Study of Lutetium (Lu-177) Oxodotreotide Injection in Subjects with Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Phase 3
Last update: May 19
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase 1
A IIT Study of Lu-177-DOTA-SNA040
Early Phase 1
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Phase 2
Last update: May 18
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants with Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
[F-18]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
N/A
Last update: May 15
Observational Study on Lutetium (Lu-177) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
Flotufolastat F 18 PET in Men with Very Low PSA Recurrence
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu-177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells